Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1265

Utomilumab

Home » Utomilumab

Background of Utomilumab

Utomilumab(PF-05082566), is a recombinant IgG2 lambda, humanized monoclonal antibody produced in CHO cell culture, which binds specifically to 4-1BB(CD137), a receptor protein found in many immune cells, such as T-cells and NK cells. And when Utomilumab binds to 4-1BB, it has been observed to stimulate and increase the number of immune cells.

Specifications

Catalog Number:
KB-1265
Antibody Name:
Utomilumab
Isotype:
Human IgG2,lambda
FC Muations:
WT
Target:
CD137
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Ajay K. Gopal, Ronald Levy, Roch Houot, Sandip P. Patel, Leslie Popplewell, et al. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clin Cancer Res. CCR-19-2973 Published June 2020.